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A highly successful symposium on ‘Molecular Biology of Cancer’ 
was held in Copenhagen at the end August 1993, as the first of a series 
of annual International Symposia sponsored by the Danish Cancer 
Society. The symposium, which in six session described the most 
recent progress in our knowledge of mutations leading to a fully 
malignant phenotype of normal cells, was intended to allow young 
Danish scientists to confront leading scientists in the field of tumour 
molecular biology. The meeting gave an overview of changes occur- 
ring in cancer cells covering (i) the relaxation of cell cycle control and 
the action of oncogenes and tumour suppressor genes via transcription 
factors, and (ii) the multiple steps of the cytoplasmic signal pathways 
creating links to the membrane-anchored receptor kinases, and 
growth factors eliciting the receptor responses. 
During the first session, ‘The Nestor of Cell Cycle Control’, A. 
Pardee (Boston) introduced the possible involvement of cyclin E and 
cdk2 as factors implicated in overcoming the cell cycle restriction point 
between G, and S phase. Specific promoter elements and the presence 
of transcription factors, among others the E2F, are crucial for the 
appearance of the cyclin E protein, which was found to be present in 
modified molecular forms in tumour cells. David Beach widened the 
cyclin story by describing his analysis of molecular complexes in anti- 
body co-precipitates of the many cyclins and the five different cell 
cycle-dependent kinases (cdk’s). Remarkably different co-precipita- 
tion patterns were observed between normal and transformed cells 
using antibodies directed against the cyclins or the cdk’s. A number 
of the co-precipitated proteins are being characterised. One of these 
was present in all immune complexes and corresponded to the PCNA. 
Cyclin D, which interacts with a p21 protein, PCNA and the cdk 
molecules 2,4 and 5, seems to be involved in a pre-replication step of 
the cell cycle. M. Strauss (Copenhagen) discussed the importance of 
cyclin Dl for the G,-to-S phase transition and the link between the cell 
cycle and transcription control through a coupling of cyclin Dl to the 
phosphorylation cycle of the retinoblastoma tumour suppressor pro- 
tein, pRb. 
Moving to the outside of the cells, D. Metcalf (Melbourne), pre- 
sented his elegant experiments that led to the characterisation and role 
of the glycosylated colony-stimulating factors in the development of 
myeloid leukaemia. He presented evidence showing that overproduc- 
tion of these growth factors leads only to hyperplasia. However, if the 
cells were immortal&d to continued growth e.g. by over-expression 
of the hox2.4 gene, production of CSF led to immediate leukaemic 
transformation. The family of TGFB proteins, which act as inhibitors 
of growth in normal cells, were discussed by H. Moses (Nashville). He 
showed that TGFBl elicits suppression of c-myc and N-myc expres- 
sion, and that this involves the Rb protein as well as a number of other 
factors. 
Binding of growth factors to their corresponding membrane-bound 
receptors leads to polypeptide chain dimerization and auto- 
phosphorylation at several tyrosine residues within their cytoplasmic 
chain extension. 
The ever-expanding families of such tyrosine-kinase receptors were 
discussed by C.-H. Heldin (Stockholm) for PDGFR, and T. Hunter 
(La Jolla) for the Eck family. Careful analysis of the phosphorylation 
sites and the signal transduction molecules binding to some of these 
sites traced the early steps in the signal pathway. For the PDGF 
receptor various phosphorylated tyrosines were responsible for the 
binding of PLC-J, GAP, PI3K and Src. In the case of the CSF-1 
receptor kinase, Hunter identified three autophosphorylation sites, 
one binding PI3K and being responsible for the growth response, 
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while another was binding the GRB2 adapter protein. J. Schlessinger 
complemented the story by demonstrating that binding of the GRB2 
protein to the phosphorylated tyrosine occurs through its SH2 do- 
main, guided by a rather short amino acid sequence surrounding the 
phosphotyrosine. The linking up to downstream effector proteins, like 
the SOS protein, was ensured through the two SH3 domains of the 
GRB2 making the SOS able to act as an exchange factor bringing the 
rus protein into its active GTP form. 
Oncogenes, which are one of the factors involved in the cascade of 
the different signal pathways, were next under scrutiny. M. Barbacid 
(Princeton) presented an overview of the many oncogenes character- 
ised in his laboratory but concentrated mainly on the p95-vuv protein 
which becomes oncogenic following removal of its N-terminal helix- 
loop-helix motif. I+zv, which is only expressed in hematopoetic ells, 
is tyrosine phosphorylated but does not work through rus. A specific 
alkaloid inhibitor of tyrosine kinases that is not toxic to cells reverses 
t&-transformed cells to a normal phenotype. The meticulous mapping 
of the Ras protein by deletions and point mutations was described by 
B. Willumsen (Copenhagen). She presented experiments that defined 
the domains essential for the rus-transforming activity. The C-termi- 
nal domain was identified as essential for membrane anchoring, 
whereas others domains are involved in the interaction with GAP and 
neurofibromin, which in turn increase the GTPase activity of the Ras 
protein. 
Turning to oncogenes localised in the nucleus K. Alitalo (Helsinki) 
concentrated his presentation on myc, while M. Yaniv (Paris) dis- 
cussed the role of the junlfos family. 
The serine phosphorylated Myc proteins, which are de-regulated in 
several human tumours, function in a heterodimeric form in conjunc- 
tion with Max as a transcription factor that binds to CACGTG se- 
quences. In several small cell carcinoma cell lines the myc gene is fused 
(by intrachromosomal re-arrangements) to the rJ gene. Serine phos- 
phorylation also brings the Jun and Fos proteins to the nucleus, 
forming JunlFos dimers that act as a transcription factor binding to 
TCACTCA motifs. Antibodies raised against members of the jun gene 
family were used to assay for the presence of Jun proteins. As a note 
to researchers, it was emphasised that the mere shaking of a cell 
culture led to a burst in both c-Jun and c-Fos synthesis. The mtsl gene, 
which has been identified as one of the few genes pecifically expressed 
in metastatic ells, was discussed by E. Lukanidin (Copenhagen). The 
gene, which is able to transform cells upon transfection, codes for a 
101 amino acid protein belonging to the S-100 family of Ca” binding 
proteins. The protein is found localised to the perinuclear egion of 
metastatic ells. 
Viruses, as tools to study tumour development, were discussed by 
M. Strauss (Copenhagen), F. Skou Pedersen (Arhus) H. zurHausen 
(Heidelberg) and J. Wyke (Glasgow). 
The tumorigenic activity of the DNA viruses, SV40, adeno virus and 
the HPVs, relate to virus-coded proteins that are capable of interacting 
with the tumour-suppressor proteins pRb and ~53, thus leading to a 
loss of their repressor functions. The late onset of tumours in virus- 
infected individuals, however, points towards a more complex course 
of tumorigenic events that includes the down-regulation of viral pro- 
teins. In the murine leukaemia virus studied by F. Skou Pedersen, the 
enhancer epeat sequences of the U3 region are a major direct determi- 
nant of lymphomagenesis. However, the interplay between the integra- 
tion site of provirus and its surrounding chromosomal DNA, which 
were recovered by PCR amplifications, was studied relative to the 
activation of neighbouring enes. 
187 
Volume 336, number 1 FEBSLE-M’ERS December 1993 
Another tumorigenic retrovirus, the Rous sarcoma virus, carrying 
the v-src oncogene coding for a non-receptor tyrosine kinase protein, 
was discussed by J. Wyke. All infected rat cells expressing the viral 
genes carry a provirus located either close to CpG islands at 5’ posi- 
tions or with contiguous 5’ duplications. Activation of v-src increases 
transcription factor AP-1 activity that is essential for exit of the cells 
from the G, phase. 
R. Sager (Boston) described her efforts to identify tumour-suppres- 
sor genes in breast cancer cells by looking for proteins over-expressed 
in normal cells. Using the differential display PCR technique coupled 
to expression cloning, she and her colleagues isolated about 30 such 
clones. Most of these coded for proteins with well-known sequences, 
while only a few were unknown. One of these clones, which is under 
further scrutiny, codes for a protease inhibitor, maspin, with sequence 
homology to anti-trypsin. 
The future trends were covered in four eminent lectures, all empha- 
sising different important approaches to the study of the molecular 
biology of cancer cells. 
M. Capecchi (Salt Lake City) described aseries ofexperiments using 
the fascinating technique of gene targeting in mice where DNA, in- 
jected into the mouse embryo-derived stem cells, disrupts the gene in 
question through homologous recombination. It was carefully demon- 
strated that four complexes of very closely related hox genes, each of 
a size of about 150 kb, govern the anterior-posterior development of 
the embryo in a co-linear fashion. The linear order of these genes, 
which are involved in determining the growth rate of specific groups 
of cells, seems to determine the three-dimensional structure of body 
elements. 
The importance of molecular biology in cancer epidemiology was 
stressed by C. Harris (Bethesda) in his description of the spectrum of 
p53 mutations in human cancer. He emphasised that about 50% of all 
human cancers carry mutations in the ~53, and that these occur in 
several hot-spots. The location of the hot-spots and frequency of 
specific transitions and transversions reflects the exposure to carcino- 
gens, making the analysis of importance in the epidemiology of many 
types of cancers. 
Protein domains capable of activating mammalian transcription 
were characterised in known transcription factors and new domains 
were cloned by W. Schaffner (Zurich), using a modification of the 
enhancer trap technique. The method, which uses plasmid constructs 
under replication control of the SV4O origin, is designed so that only 
those plasmids which have collected DNA containing an activator 
domain will replicate in monkey cells. Using viral DNA as source 
material the method has been able to collect the known activator 
domains. 
The combination of epidemiology, classical genetics and molecular 
biology that has been used to search and clone the BRCAl gene 
involved in the inherited susceptibility to breast and ovarian cancers 
was described by M.-C. King (Berkeley). YAc’s covering a 4 Mb 
section of chromosome region 17q2 1.1 were analysed for the localisa- 
tion of the BRCAl gene and candidate clones from a fibroblast cDNA 
library are currently being screened and tested for the presence of 
mutations likely to be found among tumour cells. 
J. Celis (Arhus) gave the closing lecture of the Symposium described 
his meticulous efforts to create a 2-D gel protein map of the entire 
protein population of selected human cell types and to incorporate 
these data, together with sequences and functional information, into 
a comprehensive database. This opens new perspectives to pinpoint 
proteins involved in regulatory functions in different types of normal 
and malignant cells. 
During the Symposium, the Danish Cancer Society Lecture was 
given by J.F. Rehfeld (Copenhagen). He described his work on the 
expression of gastrin and cholecystokinin in different tumours. 
Whereas gastrin was found to be generally expressed in many different 
types of cancers, CCK expression is restricted to certain neuroendo- 
crine tumours, thus opening up new diagnostic perspectives. 
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